Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000539032 | SCV000632618 | likely benign | Carnitine palmitoyltransferase II deficiency | 2024-01-24 | criteria provided, single submitter | clinical testing | |
Gene |
RCV003332190 | SCV004040452 | uncertain significance | not provided | 2023-04-02 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Ambry Genetics | RCV003372744 | SCV004061953 | uncertain significance | Inborn genetic diseases | 2023-06-23 | criteria provided, single submitter | clinical testing | The c.985G>T (p.D329Y) alteration is located in exon 4 (coding exon 4) of the CPT2 gene. This alteration results from a G to T substitution at nucleotide position 985, causing the aspartic acid (D) at amino acid position 329 to be replaced by a tyrosine (Y). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV000539032 | SCV001454235 | uncertain significance | Carnitine palmitoyltransferase II deficiency | 2020-09-16 | no assertion criteria provided | clinical testing |